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Table 1. Patient Baseline Characteristics
Table 2. Outcomes
• Electronic health record (EHR)-based retrospective 
and prospective study of patients treated in ED with 
4F-PCC for warfarin reversal
• Study was designed to replicate other retrospective 
studies and was implemented on January 19, 2021
• Study population:
• Patients ≥ 18 years admitted to the 
ED requiring anticoagulation 
reversal with 4F-PCC
• Exclusion criteria:
• Admission INR < 2.0 or no initial 
INR
• Repeat INR drawn ≥ 24 hours after 
4F-PCC administration
• Not on warfarin prior to admission or 
dose of 4F-PCC not fitting 
manufacturer weight-based dosing 
or fixed dose regimen
• The primary outcome required repeat INR to be 
drawn within 6 hours as 10 mg of Vitamin K IV is part 
of the administration protocol for warfarin reversal and 
has shown to increase coagulation factors within 1-2 
hours, having a peak effect in 12-14 hours.
• Patients who did not have repeat INR 
drawn within 6 hours of 4F-PCC 
infusion were included in analysis.
• INR was chosen as a common primary endpoint in 
past studies used to determine effective 
hemostability.2
• An INR of ≤ 1.5 was chosen as a secondary endpoint 
based on data that factor activity levels exceed 80% 
at this range, which is above the minimum hemostatic 
level.
• TEE was defined as any thromboembolic event 
identified using imaging and listed in the diagnosis of 
acute problems within 7 days of 4F-PCC infusion.
Clinical Outcomes
• Similar safety and efficacy outcomes for fixed dose 
4F-PCC can be seen when compared to weight-
based dosing.
• The median INR collection-to-result times for patients 
assessed was 34 minutes.
• Baseline INR results are not required 
for the initiation of fixed dose 4F-PCC.
Projected Savings
• Using lowest to highest acquisition costs to hospitals 
projects $45,600 - $80,400 in annual savings using 
fixed dose 4F-PCC for 55 patients.
Study Limitations
• Retrospective, non-randomized study
• The study did not reach the size required for 
adequate power to assess the primary outcome of 
INR reversal.
• Patients were not matched for baseline 
characteristics, no patients assessed in higher fixed 
dose group.
• INR not collected for all patients at 1 hour, 6 hour, and 
24 hour mark.
• Order set withdrawal after study implementation 
contributed to decreased fixed dose administration.
• Number of patients seen at the emergency 
departments may be skewed with the ongoing 
COVID-19 pandemic.
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• 4 Factor Prothrombin Complex Concentrate (4F-
PCC) reverses anticoagulation of warfarin with 
weight-based dosing criteria supplied by 
manufacturer. INR must be processed before 4F-
PCC is prepared. This regimen provides additional 
cost and delay of treatment to the patient as well as 
cost to the hospital and pharmacy department.
• Fixed dose regimens of 4F-PCC have been 
described in literature1,2-4 as having similar 
performance in achieving target INR compared to 
weight-based dosing, and can potentially have a 
decreased rate of thromboembolic events (TEE) 
compared to weight-based dosing, although large 
randomized-control trials on the comparison have 
not been conducted.
• Fixed dosing of 4F-PCC is included in the American 
College of Cardiology 2020 consensus statement for 
emergency reversal of warfarin.5
• Fixed doses of 4F-PCC for warfarin reversal were 
recommended across 8 hospitals as an option 
alongside manufacturer weight-based dosing:
• 1500 units for all adult patients
• 500 additional units for patients 
presenting with INR > 7.5 and/or 
total body weight (TBW) > 100 kg
• Fixed dose 4F-PCC did not result in decreased 
efficacy or safety when compared to weight-based 
dosing.
• Fixed dose 4F-PCC shows significant potential 
savings once implemented in a hospital.
Purpose
• To determine whether the treatment regimen of 
fixed dose 4F-PCC has similar outcomes in safety 
and efficacy when compared to manufacturer 
weight-based dosing for warfarin reversal
Methodology
• Identify percentage of eligible patients receiving 4F-
PCC within emergency departments for warfarin 
reversal
• Evaluate the percentage of patients reaching the 
primary endpoint of achieving an INR ≤ 2.0 after a 
single dose of 4F-PCC
• Assess secondary outcomes of mortality, TEE, 
blood product use, achieving INR ≤ 1.5, repeat 4F-
















Weight, kilograms, mean 84.4 (range 40.4-214.1) 75.6 (range 38.8-98.5)
Admission INR, No. (%)
INR  2 - < 4 62 (80.5) 6 (100)
INR   4 – 6 6 (7.8) 0 (0)
INR   > 6 9 (11.7) 0 (0)
4F-PCC Indication, No. (%)
GI/GU bleeding 44 (57.1) 2 (33.3)
Emergent reversal 15 (19.4) 1 (16.7)
Intracranial hemorrhage 15 (19.4) 2 (33.3)
Other 3 (3.8) 1 (16.7)




Fixed Dose Group (n=6)
INR ≤  2.0, No. (%) 64 (83.1) 6 (100)
No repeat INR in 6 hours 12 (15.5) 0 (0)
Secondary Outcomes
INR ≤ 1.5 in 6 hours 56 (72.7) 6 (100)
INR ≤ 1.5 in 24 hours 3 (3.9) 0 (0)
Mortality in 7 days, No. (%) 3 (3.8) 0 (0)
TEE within 7 days, No. (%) 1 (1.2) 0 (0)
Blood products within 7 days 37 (48.1) 2 (33.3)*
Repeat dose of 4F-PCC CI 0 (0)
CI = contraindicated; blood product = fresh frozen plasma, platelets, packed red blood cells, and/or blood; INR = international 
normalized ratio; TEE = thromboembolic event





INR 1 Hour After 
4F-PCC, mean
INR 6 Hours After 
4F-PCC, mean





Admission INR 2 - < 4 3.49 1.26 1.29 1.21
Admission INR 4 – 6 4.88 1.1 1.62 1.3
Admission INR  > 6 7.69* 1.3 1.35 1.18
Fixed Dose Group TBW < 100 kg or INR 
<7.5
2.73 1.3 1.38 1.3
*INR resulting as >10 was calculated as 10.1 for the average
Table 3. INR After 4F-PCC Infusion
